The Icos Alumni: Where Are They Now?

11/18/09Follow @xconomy

(Page 7 of 9)

Leslie Milligan, senior clinical data manager, i3StatProbe

Rosemary Monaghan, biotechnology professional

Susan Moon, freelance medical writer

Robin Moore, vice president of worldwide procurement, Getty Images [Added 12/30/09]

Amy Moro, quality assurance analyst, Quidel

Michael Moro, senior project manager of clinical supplies, Bilcare GCS

Steve Murdock, partner, life sciences practice leader, Allen Austin Executive Search

Aileen Murphy, director of biometrics, Seattle Genetics [Added 12/30/09]

Colleen Murphy, lab supply coordinator, MDRNA

Sean O’Dea, vice president of intellectual property, 3-V Biosciences

Joshua Odingo, director of chemistry, Infectious Disease Research Institute

Amy Oliver, chemicals professional

Harch Ooi, senior scientist, process chemistry, Seattle Genetics

Mark Orme, group leader of chemistry, Acucela

Karen Osofsky Michelson, senior manager of talent acquisition, Amazon.com

Karen Parker, clinical trial manager, Genentech

Leland Paul, vice president of process development, CMC Icos

Noah Pefaur, staff scientist, Novo Nordisk

Sissy Peterman, clinical research manager, Calistoga Pharmaceuticals

Scott Peterson, vice president of research and development, Oncothyreon

Tony Phan, manufacturing manager, Infectious Disease Research Institute

Louise Pobanz, finance director, CMC Icos

Tamara Potter, clinical research associate, Medicis Technologies

John Pribble, vice president of medical affairs, ZymoGenetics

Jeffrey Price, engineering technician, CMC Icos

Mark Prudhon, clinical supply manager, Seattle Genetics

Kamal Puri, principal scientist, head of biology, Calistoga Pharmaceuticals

Carol Raport, senior scientist, VLST

George Rathmann, retired

Padma Ravikumar, senior research associate, Trubion Pharmaceuticals

Mark Reed, director of medicinal chemistry, Treventis

Rob Rees, senior systems engineer, CMC Icos

Mark Rice, staff scientist, CMC Icos

Maha Rizk, scientist

Kathy Rogers, associate director, statistical programming, ZymoGenetics … Next Page »

Single Page Currently on Page: 1 2 3 4 5 6 7 8 9 previous page

By posting a comment, you agree to our terms and conditions.

  • http://www.northcoastbio.com Johnny T. Stine

    I actually loved our logo – very simple, but it just looked like fun.
    When George R. was recently asked by a reporter from an Everett newspaper about building Icos into a company like Amgen….he replied “…..why would I stop there?”. With a leader like that, like George, one who inspires with energetic goals such as that mentioned – we could’ve done it. We had the tools and the ability to do just that. We had great people who’ve all proven themselves in places before and afterward…….but imagine what we could’ve done behind the hopes of a great leader like George who set that tone….a CEO who knew all of our names, someone who would talk to you like you were a valued asset, a guy that empowered us via ownership. Imagine what we could’ve done…..because that’s all we’re left to do.

    By the way- Luke – I prefer Icosanoids – a play on the word eicosanoid since we were primarily an inflammation company. :-)

  • http://www.xconomy.com/author/ltimmerman/ Luke Timmerman

    Johnny—Unfortunately, I never really got to know George very well because he had already left Icos by the time I started covering the company in 2001. But I made a point of meeting him at his home once a couple years ago when I was based in San Francisco. He wasn’t in great health, but he was still sharp and very much curious about the latest happenings in biotech.

    I haven’t heard the term Icosanoids from eicosanoid, but that made me laugh this morning. It sounds like something from Star Trek. Anybody know if this was also the inspiration for the term “Immunoids” for people who used to work at Immunex?

  • http://www.BiotechStockResearch.com David Miller

    Nice work, Luke. Goes to prove that even though we might lose companies through acquisition we’d really rather keep, it’s not like everything connected with the company disappears. By my eye, the “loss” of Icos created at least a half-dozen new companies and significantly strengthened a dozen or more startups. A nice silver lining.

  • Abby Kliphardt

    Nice article…good to see where my co-workers have ended. I loved my time at ICOS and will always lament the loss of a great company that was a real family….

  • Pingback: The Icos Impact: What to Expect Next Week | Xconomy